Did You Know...
...Chester Carlson was a patent agent who tired of having to make multiple copies of patent applications using the only duplication method available at the time: carbon paper. In 1959 he came up with a new copying system and took it to IBM for evaluation. The "experts" at IBM determined potential sales to be only 5,000 units because people wouldn't want to use a bulky machine when they had carbon paper. Carlson's invention was the xerography process, the company founded on the system is Xerox.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 5788988 | Method for making cytoprotective, biocompatible, retrievable microcapsule containment systems The present invention is directed to a macrocapsule for encapsulating microcapsules containing biologically active material, such as living cells or free living cells, to make the system more biocompatible by decreasing the surface area and surface roughn... | 08/04/1998 |
| 5776887 | Diabetic nutritional product having controlled absorption of carbohydrate Nutritional composition for use by diabetics containing a controlled absorbed carbohydrate component. The carbohydrate component contains a rapidly absorbed fraction such as glucose or sucrose, a moderately absorbed fraction such as certain cooked starche... | 07/07/1998 |
| 5776983 | Catecholamine surrogates useful as ଲ3 agonists Compounds of the formula ##STR1## or pharmaceutically acceptable salts thereof wherein: A is a bond, --(CH2)n -- or --CH(B)--, where n is an integer of 1 to 3 and B is --CN, --CON(R9)R9' or --CO2... | 07/07/1998 |
| 5773426 | Proteoglucan and antidiabetic drug thereof This Invention is to provide a proteoglucan and an antidiabetes drug containing the proteoglucan, as an active ingredient, which possess an excellent effect against non-insulin dependent diabetes mellitus. The proteoglucan under this Invention has ଲ... | 06/30/1998 |
| 5773004 | Compositions for curing diabetes mellitus, processes for the preparation of same, and usage of same Disclosed is the composition for treating or curing diabetes mellitus containing an ingredient or component suitable for treatment of diabetes mellitus from an extract obtained by immersing a plant belonging to genus Tithonia and/or Ludwigia in a pharmaco... | 06/30/1998 |
| 5773432 | Method for lowering plasma levels of lipoprotein(a) A method of lowering plasma levels of Lp(a) or inhibiting the generation of apo(a) in a human by administering an effective amount of a compound of formula (I): ##STR1## wherein: R1 is hydrogen or alkyl; A, B, D, E, G, R2 and R | 06/30/1998 |
| 5770196 | Modified antibody variable domains and therapeutic uses thereof Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species a... | 06/23/1998 |
| 5767094 | Propiophenone derivative and processes for preparing the same A propiophenone derivative the formula I!: ##STR1## wherein R' is a lower alkanoyl group and R" is a hydrogen atom, or R' is a hydrogen atom and R" is a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof. Said compounds have ... | 06/16/1998 |
| 5763396 | Method of treating or preventing type 1 diabetes by oral administration of insulin Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to s... | 06/09/1998 |
| 5763392 | Treatment of diabetes by administration of myo-inositol Method for lowering the plasma glucose levels of diabetics by administering myo-inositol. Also the invention concerns a nutritional composition containing myo-inositol.... | 06/09/1998 |
| 5759578 | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials The present invention is directed to a macrocapsule for encapsulating microcapsules containing biologically active material, such as living cells or free living cells, to make the system more biocompatible by decreasing the surface area and surface roughn... | 06/02/1998 |
| 5760047 | Method for treatment of obesity using prolactin modulators and diet The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such treatment in combination with administration to said subjec... | 06/02/1998 |
| 5756461 | Methods for treating diabetes This invention describes methods of treating or preventing diabetes in obese type II diabetic patients. Specifically, methods of treating obese type II diabetics with varying levels of endogenous circulating leptin are claimed.... | 05/26/1998 |
| 5756513 | Therapeutic process for the treatment of the pathologies of type II diabetes A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diab... | 05/26/1998 |
| 5750497 | Acylated insulin The present invention relates to human insulin derivatives having a protracted profile of action in which the A21 and B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe... | 05/12/1998 |
| 5747539 | Fluorine-containing benzoylguanidines Fluorine-containing benzoylguanidines of the formula I ##STR1## in which R1, R2 and R3 have the meanings indicated, and their physiologically acceptable salts, have antiarrhythmic properties and act as inhibitors of t... | 05/05/1998 |
| 5747536 | Pharmaceutical composition comprising L-carnitine or derivative thereof and trihydroxy or tetrahydroxystilbene The coordinated therapeutic use of L-carnitine, lower alkanoyl L-carnitines or the pharmacologically acceptable salts thereof with resveratrol, resveratrol derivatives or resveratrol-containing natural products is disclosed for producing a medicament for ... | 05/05/1998 |
| 5747509 | Method for lowering plasma levels of lipoprotein(a) A method of lowering plasma levels of Lp(a) or inhibiting the generation of apo(a) in a human by administering an effective amount of a compound of the formula: ##STR1## wherein n is 0, 1 or 2: R1 is hydrogen, alkyl, alkanoyl, cycloalkanoy... | 05/05/1998 |
| 5741491 | Medicinal composition for diabetes The invention is a method and composition for treating diabetes using an extract derived from Heracleum lanatum and a species of Populus.... | 04/21/1998 |
| 5739138 | Enantiomerically pure hydroxylated xanthine compounds to treat autoimmune diabetes There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an ω-1 alcohol of a straight chain alkyl (C5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive com... | 04/14/1998 |
| 5731351 | Alkenyl-benzoylguanidine derivatives Alkyl-benzoylguanidines of the formula I ##STR1## wherein R1, R2 and R3 have the meanings given, and physiologically acceptable salts thereof show antiarrhythmic properties and act as inhibitors of the cellular Na | 03/24/1998 |
| 5731312 | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabete... | 03/24/1998 |
| 5731292 | Dihydrochalcone derivatives which are hypoglycemic agents A method for prophylaxis or treatment of diabetes, which comprises administering to a patient with diabetes an effective amount of a dihydrochalcone derivative of the formula I!: ##STR1## wherein Ar is an aryl group, R1 is hydrogen atom ... | 03/24/1998 |
| 5725871 | Drug delivery compositions comprising lysophosphoglycerolipid Compositions for trans-mucosal delivery, e.g. intranasal, include a lysophosphatidyl-glycerol compound as the adsorption enhancer. The preferred compounds for delivery are insulin and calcitonin.... | 03/10/1998 |
| 5719160 | Method for modifying and regulating lipid metabolism A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabete... | 02/17/1998 |
| 5718921 | Microspheres comprising polymer and drug dispersed there within A method for preparation of biodegradable polymeric drug delivery devices using relatively low temperatures and non-aqueous solutions which is particularly useful with polyanhydrides, thermolabile drugs, and in forming multi-layered devices. In a first em... | 02/17/1998 |
| 5716957 | Method for modifying and resetting the bloodstream prolactin levels of a human subject A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabete... | 02/10/1998 |
| 5716955 | Substituted imidazole compounds Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.... | 02/10/1998 |
| 5716619 | Treatment of type 2 diabetes mellitus Antibody methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to... | 02/10/1998 |
| 5716632 | Compositions and methods for reparation and prevention of fibrotic lesions In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as active ingredient(s) one or more N-sub... | 02/10/1998 |
| 5714519 | Method for regulating glucose metabolism This invention relates to a method for modifying metabolism in a vertebrate animal which entails the administration of pantethine or cysteamine at a predetermined time daily. The method is useful in the treatment of hyperglycemia, glucose intolerance, ins... | 02/03/1998 |
| 5708034 | Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them Sulfonimidamides of the formula I ##STR1## in which at least one of the three substituents R(1), R(2) and R(3) is a ... | 01/13/1998 |
| 5707644 | Small particle compositions for intranasal drug delivery A drug delivery composition for intranasal delivery comprises a plurality of bioadhesive microspheres and active drug associated with each microsphere, at least 90 wt % of the microspheres having a diameter in the range 0.1 μm to 10 μm. The microspheres... | 01/13/1998 |
| 5700839 | Alkyl-5-methylsulfonylbenzoylguanidine derivatives Benzoylguanidines of the formula I ##STR1## wherein R1 and R2 have the meanings indicated herein, and their physiologically acceptable salts, show anti-arrhythmic properties and act as inhibitors of the cellular NA+ /... | 12/23/1997 |
| 5700795 | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of type II diabetes Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administr... | 12/23/1997 |
| 5698516 | Biologically active vasopressin analogues Vasopressin analogues of formula (I) ##STR1## wherein X is (S)-2-amino-2-methyl-butanoic acid (CaMeAbu) or Valine (Val), Y is Thienylalanine (Thi) or Methionine (Met), Z is D-Phenylalanine (D-Phe) or D-Thienylalanine (Thi) or D-Tyrosine (D-Tyr), are ... | 12/16/1997 |
| 5693664 | Use of R-(+)--lipoic acid, R-(-)dihydrolipoic acid and metabolites in the form of the free acid or salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae The invention relates to the use of R-(+)--lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insul... | 12/02/1997 |
| 5686411 | Amylin agonist peptides and uses therefor Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.... | 11/11/1997 |
| 5684047 | 4-guanidinobutyramide for improving blood circulation The subject invention pertains to methods of using 4-guanidinobutyramide, or a physiologically-acceptable salt thereof, in a mammal or human to improve blood circulation.... | 11/04/1997 |
| 5679377 | Protein microspheres and methods of using them Biodegradable, protein microspheres for in vivo release of a biologically active agent, as well as agricultural and environmental applications. The microspheres can be administered orally, intravenously, or subcutaneously for subsequent release. By select... | 10/21/1997 |
